American Journal of Obstetrics & Gynecology
Volume 201, Issue 5 , Pages 466.e1-466.e7 , November 2009

Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis

Presented at the 27th Annual Meeting of the Society for Maternal-Fetal Medicine, Dallas, TX, Jan. 28-Feb. 2, 2008.

Received 16 March 2009 ,Revised 16 May 2009 ,Accepted 20 July 2009.

References 

  1. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outcome. JAMA. 1986;256:1904–1908
  2. Stagno S. Cytomegalovirus. In:  Remington JS,  Klein JO,  Baker C,  Wilson CB editor. Infectious diseases of the fetus and newborn. Philadelphia: WB Saunders; 1995;p. 312–353
  3. Hagay ZJ, Biran G, Ornoy A, Reece EA. Congenital cytomegalovirus infection: a long-standing problem still seeking a solution. Am J Obstet Gynecol. 1996;174:241–245
  4. Yow MD, Williamson DW, Leeds LJ, et al. Epidemiologic characteristics of cytomegalovirus infection in mothers and their infants. Am J Obstet Gynecol. 1988;158:1189–1195
  5. Bodeus M, Feyder S, Goubau P. Avidity of IgG antibodies distinguishes primary from non-primary cytomegalovirus infection in pregnant women. Clin Diagn Virol. 1998;9:9–16
  6. Collinet P, Subtil D, Houfflin-Debarge V, Kacet N, Dewilde A, Puech F. Routine CMV screening during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2004;114:3–11
  7. Dangel V, Bader U, Enders G. Improvement of cytomegalovirus avidity testing by adjusting the concentration of CMV-specific IgG in test samples. J Clin Virol. 2006;35:303–309
  8. Duff P. A thoughtful algorithm for the accurate diagnosis of primary CMV infection in pregnancy. Am J Obstet Gynecol. 2007;196:196–197
  9. Grangeot-Keros L, Mayaux MJ, Lebon P, et al. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J Infect Dis. 1997;175:944–946
  10. Lazzarotto T, Guerra B, Spezzacatena P, et al. Prenatal diagnosis of congenital cytomegalovirus infection. J Clin Microbiol. 1998;36:3540–3544
  11. Lazzarotto T, Spezzacatena P, Pradelli P, Abate DA, Varani S, Landini MP. Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin Diagn Lab Immunol. 1997;4:469–473
  12. Lazzarotto T, Varani S, Spezzacatena P, et al. Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus. Viral Immunol. 2000;13:137–141
  13. Mace M, Sissoeff L, Rudent A, Grangeot-Keros L. A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women. Prenat Diagn. 2004;24:861–863
  14. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353:1350–1362
  15. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583–637
  16. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 3—estimating probabilities and utilities. Med Decis Making. 1997;17:136–141
  17. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005;
  18. Lazzarotto T, Spezzacatena P, Varani S, et al. Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. Clin Diagn Lab Immunol. 1999;6:127–129
  19. Ruellan-Eugene G, Barjot P, Campet M, et al. Evaluation of virological procedures to detect fetal human cytomegalovirus infection: avidity of IgG antibodies, virus detection in amniotic fluid and maternal serum. J Med Virol. 1996;50:9–15
  20. Lazzarotto T, Varani S, Guerra B, Nicolosi A, Lanari M, Landini MP. Prenatal indicators of congenital cytomegalovirus infection. J Pediatr. 2000;137:90–95
  21. Nigro G, La Torre R, Anceschi MM, Mazzocco M, Cosmi EV. Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction. Am J Obstet Gynecol. 1999;180:1222–1226
  22. Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med. 2002;347:233–239
  23. Decreasing incidence of perinatal group B streptococcal disease—United States, 1993-1995. MMWR Morb Mortal Wkly Rep. 1997;46:473–477
  24. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr. 2004;145:485–491
  25. Adler SP, Nigro G, Pereira L. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin Perinatol. 2007;31:10–18
  26. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA. 2003;289:1008–1011
  27. Clinical Trials Registry. http://www.clinicaltrials.gov/Accessed March 15, 2009
  28. Ross DS, Dollard SC, Victor M, Sumartojo E, Cannon MJ. The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup. J Womens Health (Larchmt). 2006;15:224–229
  29. Pass RF, Stagno S, Myers GJ, Alford CA. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics. 1980;66:758–762
  30. Yinon Y, Yagel S, Tepperberg-Dikawa M, Feldman B, Schiff E, Lipitz S. Prenatal diagnosis and outcome of congenital cytomegalovirus infection in twin pregnancies. BJOG. 2006;113:295–300
  31. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43:1143–1151
  32. Marshall GS, Stout GG. Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period. Am J Perinatol. 2005;22:371–376
  33. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007;7:71
  34. Lazzarotto T, Gabrielli L, Lanari M, et al. Congenital cytomegalovirus infection: recent advances in the diagnosis of maternal infection. Hum Immunol. 2004;65:410–415
  35. Pass RF, Little EA, Stagno S, Britt WJ, Alford CA. Young children as a probable source of maternal and congenital cytomegalovirus infection. N Engl J Med. 1987;316:1366–1370
  36. Aboujaoude R, Alvarez J, Ganesh V, Apuzzio J. Is testing for cytomegalovirus and cystic fibrosis indicated in members of a nonwhite pregnant population in whom the fetus has an echogenic bowel?. Am J Perinatol. 2006;23:319–323
  37. Liesnard C, Donner C, Brancart F, Gosselin F, Delforge ML, Rodesch F. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol. 2000;95:881–888
  38. Guerra B, Simonazzi G, Banfi A, et al. Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers. Am J Obstet Gynecol. 2007;196:221.e1–221.e6
  39. Eddleman KA, Malone FD, Sullivan L, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol. 2006;108:1067–1072
  40. Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol. 2008;111:589–595
  41. Azam AZ, Vial Y, Fawer CL, Zufferey J, Hohlfeld P. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol. 2001;97:443–448
  42. Lipitz S, Yagel S, Shalev E, Achiron R, Mashiach S, Schiff E. Prenatal diagnosis of fetal primary cytomegalovirus infection. Obstet Gynecol. 1997;89:763–767
  43. Renal insufficiency and failure associated with immune globulin intravenous therapy—United States, 1985-1998. MMWR Morb Mortal Wkly Rep. 1999;48:518–521
  44. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326:663–667
  45. Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics. 1999;104:55–60
  46. Pham CT, Crowther CA. Birth outcomes: utility values that postnatal women, midwives and medical staff express. BJOG. 2003;110:121–127
  47. Vandenbussche FP, De Jong-Potjer LC, Stiggelbout AM, Le Cessie S, Keirse MJ. Differences in the valuation of birth outcomes among pregnant women, mothers, and obstetricians. Birth. 1999;26:178–183
  48. Caughey AB, Kuppermann M, Norton ME, Washington AE. Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol. 2002;187:1239–1245
  49. Harris RA, Washington AE, Nease RF, Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet. 2004;363:276–282
  50. Odibo AO, Stamilio DM, Nelson DB, Sehdev HM, Macones GA. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Obstet Gynecol. 2005;106:562–568
  51. Waitzman NJ, Romano PS, Scheffler RM. Estimates of the economic costs of birth defects. Inquiry. 1994;31:188–205
  52. Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventative Task Force: a review of the process. Am J Prev Med. 2001;20(3S):

 Cite this article as: Cahill AG, Odibo AO, Stamilio DM, et al. Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis. Am J Obstet Gynecol 2009;201:466.e1-7.

 Reprints not available from the authors.

PII: S0002-9378(09)00842-4

doi: 10.1016/j.ajog.2009.07.056

American Journal of Obstetrics & Gynecology
Volume 201, Issue 5 , Pages 466.e1-466.e7 , November 2009

Article Tools